Cancer

News

Gilead poaches oncology expert Quigley from BMS

Gilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of research biology.

News

BMS builds case for long-term use of Opdivo in kidney cancer

Bristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, showing that more than a quarter of patients were alive after fiv

News

Epizyme eyes lucrative use for newly-launched Tazverik

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.

News

Jazz targets US launch of SCLC drug after FDA grants fast re...

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

News

FDA to fast-track review of BMS' CAR-T, ahead of shareholder...

Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene's merger with Bristol-Myers Squibb, after the FDA agreed to fast-track its review of a n

News

NICE rejects MSD/Pfizer's combination in untreated kidney ca...

NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon

Gilead poaches oncology expert Quigley from BMS

BMS builds case for long-term use of Opdivo in kidney cancer

Epizyme eyes lucrative use for newly-launched Tazverik

Jazz targets US launch of SCLC drug after FDA grants fast re...

FDA to fast-track review of BMS' CAR-T, ahead of shareholder...

NICE rejects MSD/Pfizer's combination in untreated kidney ca...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Cancer

Editor's Picks